Core Viewpoint - The company, Junshi Biosciences (复宏汉霖), has announced the completion of the first patient dosing in a Phase 2/3 clinical study of HLX22 in combination with HLX87 for the treatment of HER2-positive recurrent or metastatic breast cancer in mainland China [1][2]. Group 1: Clinical Study Overview - The study is an open-label, randomized, multi-center Phase 2/3 clinical trial evaluating the efficacy of HLX22 combined with HLX87 in treating HER2-positive recurrent or metastatic breast cancer patients [2]. - The first phase involves a randomized, parallel-controlled design with a 2:2:1:1 allocation ratio for participants receiving HLX22 combined with HLX87, or other combinations including pertuzumab and trastuzumab [2]. - The primary endpoints for the first phase include objective response rate (ORR) and progression-free survival (PFS) assessed by an independent imaging review committee (BICR) [2]. Group 2: Study Objectives and Design - The second phase of the study is also an open-label, randomized, multi-center trial, with participants allocated in a 1:1 ratio to receive either HLX22 combined with HLX87 or pertuzumab combined with trastuzumab and docetaxel [2]. - The main objective of the study is to evaluate the clinical efficacy of HLX22 combined with HLX87 in treating HER2-positive recurrent or metastatic breast cancer, while secondary objectives include assessing safety, tolerability, pharmacokinetics (PK), immunogenicity, and exploring potential predictive or resistance biomarkers [2].

Core Viewpoint - The company, Junshi Biosciences (复宏汉霖), has announced the completion of the first patient dosing in a Phase 2/3 clinical study for HLX22, a humanized anti-HER2 monoclonal antibody injection, in combination with HLX87, a targeted HER2 antibody-drug conjugate, for the treatment of HER2-positive recurrent or metastatic breast cancer patients in mainland China [1] Group 1 - The clinical study is focused on HER2-positive recurrent or metastatic breast cancer patients [1] - HLX22 is a restructured humanized anti-HER2 monoclonal antibody injection [1] - HLX87 is a targeted HER2 antibody-drug conjugate [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 Shanghai Henlius Biotech, Inc. 上海復宏漢霖生物技術股份有限公司 自願公告 帕妥珠單抗生物類似藥HLX11 （重組抗HER2結構域II人源化單克隆抗體注射液） 獲歐洲藥品管理局(EMA)人用醫藥產品 委員會(CHMP)積極審評意見 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2696） A. 緒言 本公告由上海復宏漢霖生物技術股份有限公司（「本公司」）自願作出，以告知 本公司股東及潛在投資者本公司最新業務更新。 茲提述本公司於2025年3月28日刊發的公告，內容有關本公司自主研發的 Perjeta® （帕妥珠單抗）生物類似藥候選藥HLX11（重組抗HER2結構域II人源 化單克隆抗體注射液）（「HLX11」）適用於：(1)與曲妥珠單抗和化療聯合(i)用 於HER2陽性、局部晚期、炎性或早期乳腺癌且具有高復發風險成人患者的 新輔助治療；以及(ii)用於具有高復發風險 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 Shanghai Henlius Biotech, Inc. 上海復宏漢霖生物技術股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2696） 自願公告 HLX22（重組人源化抗HER2單克隆抗體注射液）聯合注射用HLX87 （靶向HER2抗體偶聯藥物）一線治療HER2陽性復發或轉移性 乳腺癌(BC)患者的2/3期臨床研究於中國境內完成首例患者給藥 A. 緒言 B. 臨床試驗設計及目的 本研究是一項評估HLX22聯合HLX87一線治療HER2陽性復發或轉移性乳腺 癌患者的開放、隨機、多中心的2/3期臨床研究。研究包括兩個階段，第一階 段是一項開放、多中心、隨機、平行對照的2期臨床研究，合格受試者將按照 2:2:1:1的比例隨機分配接受HLX22聯合HLX87、帕妥珠單抗聯合HLX87、帕 妥珠單抗聯合德曲妥珠單抗或帕妥珠單抗聯合曲妥珠單抗及多西他賽治療。 第一階段的主要終點是獨立影像評 ...

Core Viewpoint - The company, Bibet (688759.SH), reported no operating revenue for the fiscal year 2025, indicating significant financial challenges ahead [1] Financial Performance - The net profit attributable to the parent company's owners was -153.08 million yuan, with losses increasing by 97.08 million yuan year-on-year [1] - The net profit attributable to the parent company's owners, excluding non-recurring gains and losses, was -175.42 million yuan, with losses increasing by 17.37 million yuan year-on-year [1]

Core Viewpoint - The company reported significant growth in its 2025 performance, driven by strong overseas market expansion and successful product launches [2] Financial Performance - In 2025, the company achieved total revenue of 1.541 billion yuan, representing a year-on-year increase of 9.54% [2] - The net profit attributable to the parent company reached 159 million yuan, a substantial increase of 406.47% compared to 31.48 million yuan in the same period of 2024 [2] Market Expansion - The company's overseas revenue saw significant growth, contributing to the overall increase in revenue and profit [2] - The company has established a global market presence in approximately 70 countries and regions, including the EU, Brazil, the Philippines, and Indonesia [2] - The company's core product, albumin paclitaxel, was approved for sale in the EU in 2024, with export volume in the first half of 2025 accounting for 47.7% of China's total exports of similar products [2] Innovation and R&D - The company's long-term commitment to innovation and R&D has entered a phase of成果转化 (results transformation), contributing to its explosive growth [2] - The company focuses on three potential areas: oncology, autoimmune diseases, and metabolic diseases, advancing a differentiated pipeline [2] - Several products with "first-in-class" (FIC) or "best-in-class" (BIC) potential have entered critical clinical stages, injecting new momentum for long-term value growth [2]

Core Viewpoint - Changchun Gaoxin has received clinical approval for treatments targeting specific conditions related to hormone deficiencies and congenital adrenal hyperplasia, indicating a focus on niche medical needs and potential market opportunities [2] Group 1 - The company has been approved for clinical indications to improve conditions caused by hypergonadotropic hypogonadism, 5α-reductase type 2 deficiency, congenital adrenal hyperplasia, and idiopathic causes leading to penile hypoplasia in children [2] - The company commits to fulfilling disclosure obligations as per legal regulations if new situations arise that meet disclosure standards in the future [2]

证券日报网讯 2月27日，亚虹医药发布公告称，公司2025年实现营业总收入27712.15万元，同比增长 37.49%；归属于母公司所有者的净利润为-41934.08万元，亏损较上年同期扩大。 （文章来源：证券日报） ...

Core Insights - Huaxi Biological Technology Co., Ltd. reported a total revenue of 4.217 billion yuan for the fiscal year 2025, representing a year-on-year decline of 21.49%. However, the net profit attributable to the parent company reached 291 million yuan, marking a significant increase of 67.03% [2][3] Revenue Performance - The decline in revenue is attributed to the company's proactive structural adjustments, which involved optimizing the C-end brand system, product structure, and channel models, leading to a temporary revenue contraction [2] - The company has focused on reducing inefficient brands and sales activities based solely on revenue metrics, which has impacted short-term income [2] Profitability Improvement - The strategic adjustments have resulted in a notable improvement in profitability, with management and sales expenses decreasing by over 10% and 30% year-on-year, respectively [2] - Cost reduction measures included integrating overlapping departments, optimizing organizational levels, and improving inventory structure, allowing the company to shift from "scale expansion" to "quality growth" [2] Research and Development - Huaxi Biological continues to deepen its focus on glycoscience and cell biology, leveraging a synthetic biology platform to accelerate the conversion of research outcomes into products, laying a foundation for long-term development [2] - The application of digital and AI technologies in production, manufacturing, and supply chain management has further enhanced operational efficiency [2] Additional Factors - The increase in government subsidies, fair value changes of investment projects, and gains from equity investment disposals contributed to the significant change in net profit, especially given the low base of 174 million yuan in the same period of 2024 [3]

Core Viewpoint - The company, I-Wu Biotech, has received approval for a clinical trial supplement application for its drug "Dog Hair Dander Prick Liquid" from the National Medical Products Administration [2] Group 1 - The approval was obtained from the National Medical Products Administration's government service portal [2] - The clinical trial supplement application was submitted by the company [2]